Medical Oncologist
Your treatment plan
Neoadjuvant treatment in triple-negative breast cancer
Chemotherapy is given before surgery in most triple negative breast cancers because these cancers respond quickly and often completely, and because the response itself decides what treatment follows. This page explains what the course usually contains, what each outcome at surgery leads to, and why genetic testing should be arranged early rather than late.
NG
Medically reviewed by Dr. Naresh GunduConsultant Medical Oncologist · MBBS, DNB (Internal Medicine), DM (Medical Oncology, AIIMS) · last reviewed September 2026, next review due September 2027
On this page
- Why is chemotherapy given first in triple negative breast cancer?
- What the course usually contains
- What happens, in order
- The vocabulary, in plain language
- The two results, and what each leads to
- What is honest about this diagnosis
- What families are told about triple negative cancer
- Common questions about triple negative treatment
The short answer
Why is chemotherapy given first in triple negative breast cancer?
Because these cancers respond to chemotherapy quickly and often completely, and because the response itself decides what treatment you are offered afterwards. Giving it before surgery is now the usual approach for all but the smallest triple negative cancers.
What triple negative means
The cancer has no oestrogen receptors, no progesterone receptors and no excess HER2 protein. That closes off hormone tablets and HER2 treatments, so chemotherapy does the main work. It is not a rarer or worse-behaved cancer in every case, but it does behave differently.
Why the response matters more here than anywhere
Triple negative cancers that clear completely have notably better outcomes. Those with cancer remaining are offered additional treatment after surgery, specifically chosen because of that result. Operating first means that information is never generated and that option is closed.
Who it does not suit
Very small, node-negative triple negative cancers are sometimes removed first, because the operation is straightforward and the benefit of knowing the response is smaller. Your team will say if yours falls into that group.
Ask whether immunotherapy is part of your plan, and whether genetic testing has been arranged.The treatment
What the course usually contains
Regimens differ between centres and between patients. Ask which parts apply to you.
Two families of chemotherapy
Most courses are built in two blocks using different kinds of drug, given one after the other. A cancer that responds poorly to the first block may still respond well to the second.
A platinum drug, in some plans
Adding one raises the chance of clearing the cancer completely. It also adds side effects, so it is a genuine trade-off your oncologist will discuss rather than a default.
Ask whether one is being added, and why.Immunotherapy, for many
For larger or node-positive triple negative cancers, immunotherapy is now often given alongside chemotherapy before surgery and continued afterwards. It brings its own distinct side effects.
Supportive medicines
Injections to protect your white cells, anti-sickness medicines and steroids are given as part of the plan, not as extras. They are what make the regimen deliverable on schedule.
Ask for in writing
- The name of your regimen
- How many cycles, over how long
- What is given for side effects
The pathway
What happens, in order
-
Full testing first
Biopsy, receptor and HER2 results, and scans. Genetic testing is often arranged at this point too, because a BRCA fault changes both treatment and surgical choices.
-
A marker clip is placed
Essential here, because these cancers frequently disappear completely. Without it the surgeon cannot find the original site.
-
The chemotherapy course
Several months, given in cycles, usually as day-care. Response is checked by examination before each cycle and with a scan partway through.
-
Surgery
A few weeks after the last cycle. The tissue removed shows whether any cancer remains, which is the result the whole approach was built to produce.
-
What follows depends on that result
A complete response usually means finishing radiotherapy and any immunotherapy already started. Cancer remaining usually means additional treatment after surgery.
Words you will hear
The vocabulary, in plain language
- Triple negative
- No oestrogen receptors, no progesterone receptors, no excess HER2. All three results have to be negative.
- Platinum agent
- A family of chemotherapy drug sometimes added to raise the chance of clearing the cancer completely.
- Immunotherapy
- Treatment that works through your own immune system rather than attacking cells directly. Its side effects are different in kind from chemotherapy.
- Complete response
- No invasive cancer found at surgery. The outcome this approach aims for, and a strongly reassuring one here.
- Residual disease
- Cancer still present at surgery. The trigger for additional treatment afterwards.
- BRCA
- An inherited gene fault that is more common in triple negative breast cancer and that opens particular treatments.
Talk to our team
Have a question about your situation?
Call the helpline or leave your details, and someone will help you arrange a consultation at the CION centre nearest you. One helpline serves every CION centre.
Call 1800 202 8726
Helpline open 24/7
Side by side
The two results, and what each leads to
No cancer left at surgery
Cancer still present at surgery
Strongly reassuring for this subtype
A higher risk of recurrence, and treatable
Usually no further chemotherapy
Further treatment after surgery commonly offered
Radiotherapy continues as planned
Radiotherapy continues as planned
Immunotherapy finished if it was started
Additional targeted treatment if a BRCA fault is present
Follow-up on the usual schedule
Often a good moment to ask about trials
Being straight with you
What is honest about this diagnosis
Triple negative breast cancer carries a higher risk of returning in the first few years than hormone sensitive disease, and your oncologist should say so plainly. It also responds to chemotherapy better than most subtypes, which is the other half of the picture and is often left out.
The risk is front-loaded
Where recurrence happens, it tends to happen in the earlier years rather than a decade later, which is the opposite pattern to hormone sensitive cancer. Passing those first years without a recurrence is genuinely meaningful here.
What has changed recently
Immunotherapy before surgery, and additional treatment for those with cancer remaining, are both relatively recent. Outcome figures published before these came into use describe women who could not receive them. Older numbers therefore understate where you stand.
What this page cannot tell you
It cannot tell you your own risk, because that depends on the size, the nodes, the response and your genetic result. Ask your oncologist for your own picture rather than reading general figures, and ask them to write down which treatments apply to you.
Commonly believed
What families are told about triple negative cancer
Triple negative means there is no treatment.
It means two routes are closed, not all of them. Chemotherapy works particularly well in this subtype, immunotherapy is now part of the plan for many, and targeted treatment exists where a BRCA fault is present. The list of options is shorter, not empty.
Negative results mean the tests found nothing useful.
The word negative here describes what the cancer does not carry, which is itself decisive information. It tells your team that hormone tablets and HER2 drugs will not help, so the plan is built around what does.
Waiting months for surgery is especially dangerous in this subtype.
The opposite is closer to the truth. These cancers respond fastest to chemotherapy, so the months are productive, and the response result unlocks treatment that improves outcomes for those who need it. This is the subtype where the approach pays off most.
Genetic testing can wait until treatment is over.
It should be arranged early. A BRCA result can change which chemotherapy is chosen, which surgery you are offered, and whether an additional treatment is available after surgery. Left to the end, it changes nothing that could still have been acted on.
Questions we are asked
Common questions about triple negative treatment
Is triple negative breast cancer more aggressive?
It tends to grow faster and carries a higher risk of returning in the first few years than hormone sensitive disease. It also responds to chemotherapy far better than most subtypes, and a complete response is genuinely reassuring here. Both halves of that picture are true and you should hear both.
Should I have genetic testing?
Almost certainly ask for it, because BRCA faults are more common in this subtype and the result can change your chemotherapy, your surgery and what is offered after surgery. Ask early rather than late, since a result arriving after treatment finishes cannot influence any of those decisions.
Will I get immunotherapy?
It is now commonly offered alongside chemotherapy before surgery for larger or node-positive triple negative cancers, and continued afterwards. Whether it applies to you depends on your stage and on what your centre provides. Ask directly, and ask what its side effects are, because they differ from chemotherapy.
What happens if cancer is still there at surgery?
Additional treatment after surgery is commonly offered, chosen specifically because of that result. This is one of the main reasons chemotherapy is given first in this subtype. Ask what is being added, how long it lasts, and whether a clinical trial is also open to you.
Does diet or lifestyle affect my response?
Response is determined by the biology of the cancer, not by what you eat. Eating normally and keeping your weight up matters because it helps you complete the course on schedule, and completing it does affect the outcome. Avoid restrictive diets during treatment.
Is a platinum drug better?
Adding one raises the chance of clearing the cancer completely, and it also adds side effects. Whether the trade-off is worth it depends on your situation and on what else is in your plan. Ask your oncologist to set out both sides rather than assuming more drugs is automatically better.
Can I keep my breast?
Often yes, and these cancers shrink well, which improves the chance. It depends on how much remains, where it sits, and whether a marker clip was placed. Ask for the surgical decision to be reassessed after chemotherapy rather than carried over from diagnosis.
Are there trials I should ask about?
Yes, this is an actively researched subtype and trials recruit both at diagnosis and after surgery where cancer remains. Ask what is open at your centre and whether a referral elsewhere is worth considering, and ask before the plan is finalised.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Where to find us
Our centres in and around Hyderabad
Addressed by landmark, because that is how this city navigates. Each centre also names the areas it serves, so you can place it without a map. Consultation and day-care Chemotherapy run at every one of them.
Warangal
Vizag
Talk to our team
Speak to a breast cancer specialist
Call the helpline or leave your details, and someone will help you arrange a consultation at the CION centre nearest you. One helpline serves every CION centre.
Call 1800 202 8726
Helpline open 24/7
Sources
- Cancer Research UK — Triple negative breast cancer
- National Cancer Institute — Breast cancer treatment (PDQ)
- Breast Cancer Now — Triple negative breast cancer
This page is general information, not a prescription. Do not change or stop any treatment based on what you read here. If anything is worrying you, contact your own treating team — or call our helpline and we will help you reach the right specialist.